Roche beefs up di­ag­nos­tic arm with an­oth­er bet on faster, cheap­er DNA se­quenc­ing

While Roche pours half a bil­lion dol­lars in­to its Covid-19 an­ti­body test, the Swiss com­pa­ny is qui­et­ly beef­ing up the rest of their di­ag­nos­tics arm.

Roche to­day ac­quired Stratos Ge­nomics, a Seat­tle-based de­vel­op­er of a new DNA tech­nol­o­gy de­signed to make ge­net­ic strands more easy to read. Roche said it will use the Stratos tech­nol­o­gy, along­side its ex­ist­ing ef­forts, to de­vel­op a nanopore se­quenc­ing de­vice that can quick­ly and cheap­ly read pa­tients’ DNA in clin­ics to di­ag­no­sis dis­ease and as­sess the risk of de­vel­op­ing one.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER